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Summary
Background Latent tuberculosis infection (LTBI) is one of the most prevalent infections globally and can lead to the 
development of active tuberculosis disease. In many low-burden countries, LTBI is concentrated within migrant 
populations often because of a higher disease burden in the migrant’s country of origin. National programmes 
consequently focus on screening and treating LTBI in migrants to prevent future tuberculosis cases; however, how 
effective these programmes are is unclear. We aimed to assess LTBI treatment initiation and outcomes among 
migrants, and the factors that influence both.
Methods For this systematic review and meta-analysis, we searched Embase, MEDLINE, and Global Health, and 
manually searched grey literature from Jan 1, 2000, to April 21, 2020. We included primary research articles reporting 
on LTBI treatment initiation or completion, or both, in migrants and excluded articles in which data were not stratified 
by migrant status, or in which the data were related to outcomes before 2000. There were no geographical or language 
restrictions. All included studies were quality appraised using recognised tools depending on their design, and we 
assessed the heterogeneity of analyses using I². We extracted data on the numbers of migrants initiating and 
completing treatment. Our primary outcomes were LTBI treatment initiation and completion in migrants (defined as 
foreign-born). We used random-effects meta-regression to examine the influence of factors related to these outcomes. 
The study is registered with PROSPERO (CRD42019140338).
Findings 2199 publications were retrieved screened, after which 39 publications from 13 mostly high-income, low-
burden countries were included in our analyses, with treatment initiation and completion data reported for 
31 598 migrants positive for LTBI, with not all articles reporting the full pathway from initiation to completion. The 
pooled estimate for the true proportion of migrants testing positive who initiated treatment was 69% (95% CI 51–84; 
I²= 99∙62%; 4409 of 8764). The pooled estimate for the true proportion of migrants on treatment in datasets, who 
subsequently completed it was 74% (95% CI = 66–81; I² = 99∙19%; 15 516 of 25 629). Where data were provided for 
the entire treatment pathway, the pooled estimate for the true proportion of migrants who initiated and completed 
treatment after a positive test was only 52% (95% CI 40–64; I² = 98∙90%; 3289 of 6652). Meta-regression showed that 
LTBI programmes are improving, with more recent reported data (2010–20) associated with better rates of treatment 
initiation and completion, with multiple complex factors affecting treatment outcomes in migrants.
Interpretation Although our analysis highlights that LTBI treatment initiation and completion in migrants has 
improved considerably from 2010–20, there is still room for improvement, with drop out reported along the entire 
treatment pathway. The delivery of these screening and treatment programmes will require further strengthening if 
the targets to eradicate tuberculosis in low-incidence countries are to be met, with greater focus needed on engaging 
migrants more effectively in the clinic and understanding the diverse and unique barriers and facilitators to migrants 
initiating and completing treatment.
Funding European Society of Clinical Microbiology and Infectious Diseases, the Rosetrees Trust, the National Institute 
for Health Research, and the Academy of Medical Sciences.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Approximately 25% of the global population have latent 
tuberculosis infection (LTBI),1,2 and approximately 
5–15% of those infected will develop active tuberculosis 
in their lifetime.3,4 Among contacts of patients with 
pulmonary tuberculosis, the 5-year cumulative risk of 
LTBI infection is approximately 10%, although this risk 
appears to be much greater in younger individuals, in 
whom the 5-year risk was 33∙3% in contacts younger 
than 5 years, and 19∙1% in those aged 5–14 years.5 
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Delivering effective LTBI screening and treatment 
programmes is increasingly emphasised in the control of 
tuberculosis, with WHO’s End TB strategy outlining 
expanded preventive treatment of people at higher risk of 
tuberculosis, and encouraging research to improve LTBI 
detection and treatment.6 The first UN high-level meeting 
on tuberculosis in 2018 set a target to reach 30 million 
people with preventive treatment for tuberculosis 
between 2018 and 2022, including 20 million household 
contacts, and 4 million children younger than 5 years.7
In many high-income, low-incidence tuberculosis 
countries (<10 cases per 100 000 population)8 migrants 
have a greater burden of tuberculosis, and tend to be 
younger, than native-born populations.9,10 For example, 
77∙3% of first-time asylum seekers in the 27 EU countries 
in 2019 were younger than 35 years.11 LTBI prevalence is 
probably higher in some migrant populations, with 
refugee children estimated to have LTBI prevalence 
rates of around 11%.12 High LTBI prevalence could 
drive greater active tuberculosis incidence within these 
populations, as most cases are likely to be due to re-
activation of LTBI.13 One retro spective cohort of 
142 314 people estimated a tuberculosis incidence rate of 
120 cases per 100 000 person-years among migrants 
compared with an incidence rate of 4 cases 
per 100 000 person-years in native-born individuals.10 The 
incidence of tuberculosis among migrants is greatest 
within the first 5 years of arrival, driven by health-related 
factors (eg, age and comorbid status) and socioeconomic 
factors (eg, living con ditions).9,14 WHO has published 
recommendations for low-incidence countries to con-
sider systematic LTBI testing and treatment in migrants.15 
Consequently, the European Centre for Disease 
Prevention and Control (ECDC) has developed guidance 
for the programmatic management of LTBI in migrants 
(among other groups), in line with WHO recom-
mendations.16
Increasingly, LTBI and tuberculosis screening pro-
grammes in low-incidence tuberculosis countries 
now include migrants from high-burden tuberculosis 
countries alongside other high-risk groups,17 whom are at 
greater risk of LTBI re-activation than other groups.14,18 
6–9 month courses of isoniazid therapy for LTBI are 
being increasingly replaced with shorter 3–4 month 
treatment regimens that often confer increased treatment 
completion and a reduction in complications and 
Research in context
Evidence before this study
Reactivation of latent tuberculosis infection (LTBI) is a major 
driver of tuberculosis incidence worldwide; in countries with a 
low incidence of tuberculosis, LTBI is disproportionately 
concentrated among migrants, with national programmes 
increasingly focusing on the diagnosis and treatment of LTBI in 
migrants and other high-risk groups. However, little is known 
about the success of these programmes in engaging migrants 
and ensuring treatment completion because migrants often 
face multiple barriers to accessing health care on arrival in the 
host country. We searched MEDLINE, Embase, and Global Health 
from Jan 1, 2000, to April 21, 2020 for publications on LTBI 
treatment initiation and completion in migrants. Before this 
study we found two reviews on this topic (Sandgren and 
colleagues, 2016, and Alsdurf and colleagues, 2016); however, 
neither specifically focused on migrants. Sandgren and 
colleagues included a small number of studies reporting on 
migrant outcomes and did not have a formal meta-analysis, 
and Alsdurf and colleagues used data before 2000 that might 
not be relevant to current policy. Other studies have reported on 
migrant-specific outcomes in LTBI programmes globally, but the 
focus is often on screening practices rather than outcomes and 
evidence in this area has not yet been effectively consolidated.
Added value of this study
This is a comprehensive systematic review and meta-analysis 
exploring LTBI treatment initiation and completion specifically 
among migrant populations. We report LTBI treatment 
outcome data on 31 598 migrants from 2000 onwards in 
13 low-incidence countries (<10 cases per 100 000 population). 
The research provides robust insights into the proportion of 
individuals initiating and completing treatment, using meta-
regression to explore heterogeneity. The data showed that 
between 2000 and 2020, the pooled estimate for the true 
proportion of migrants who tested positive for LTBI had 
initiated treatment was 4409 (69%) of 8764 and of those 
starting treatment, 15 516 (74%) of 25 629 completed it. 
Among studies capturing data on both initiation and 
completion, the pooled estimate for the true proportion of 
migrants who tested positive for LTBI who successfully initiated 
and completed treatment was only 3289 (52%) of 6652, with 
dropouts reported along the entire treatment pathway. 
The data also indicate higher initiation and completion of 
treatment between 2010 and 2020 than before 2010 with 
renewed focus on this approach to tuberculosis control, and a 
trend toward more positive outcomes among migrants in 
programmes in the WHO European region. The data showed 
that multiple complex factors affect treatment outcomes in 
migrants, including patient demographics and health systems.
Implications of all the available evidence
Delivery of LTBI programmes will need to be strengthened to 
improve outcomes for migrants and meet targets to eradicate 
tuberculosis in low-incidence countries. Greater focus will 
need to be placed on engaging migrants more effectively in 
the clinic, understanding the varied reasons for migrants’ 
declining treatment when testing positive, and ensuring 
treatment adherence using innovative approaches that are 
mindful of and sensitive to the unique experiences of this 
group on arrival to the host country.
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side-effects for patients that might have a positive effect 
on treatment completion.15,19 Although availability and 
use of these regimens varies by country, they could 
contribute to improved treatment completion among 
migrant patients.
Uncertainties exist regarding the effectiveness of 
LTBI screening and treatment programmes involving 
migrants. A systematic review on infectious disease 
screening among migrants to Europe revealed that 
screening often focuses on LTBI, and suggests that 54% of 
migrants with a positive LTBI test complete treatment.20 
Another systematic review and meta-analysis analysing 
the LTBI care cascade among multiple population groups 
estimated that only 54∙6% of migrants initiate treatment, 
and 14∙3% of all migrants complete treatment.21 Risk 
factors that specifically affect migrant LTBI treatment 
outcomes include legal status,21 patients’ mistrust, and 
uncertainty around legal entitlements regarding eligibility 
and access to medical care for migrants among patients 
and staff,22 and language and cultural barriers.21,23 More 
generally, logistical barriers to accessing treatment (such 
as wait times) and side-effects can affect all patient 
groups.21 Furthermore, clinician-recommended treatment 
can deviate from national guidelines because of clinician 
perceptions of the risk–benefit balance of treating 
LTBI.21,23 Facilitators to treatment such as culturally 
sensitive services, patient involvement and ownership in 
delivering care, and ensuring high-quality service 
provider management, aid screening and could benefit 
LTBI treatment.20,22 Understanding facilitators and bar-
riers to LTBI treatment initiation and completion, and key 
stages in the screening and treatment pathway in which 
migrants are lost to follow-up, is essential for informing 
where to target interventions to improve health outcomes 
for migrants.
We therefore did a systematic review and meta-analysis 
to explore and assess available evidence on the initiation 
and completion of LTBI treatment among LTBI-positive 
migrants globally to better understand whether, and 
where, efforts to improve current practices could be 
targeted.
Methods
Search strategy and selection criteria
We did a systematic review and meta-analysis to identify 
and synthesise evidence on rates and correlates of 
treatment initiation once a migrant had tested positive, 
and the completion of the full recommended course of 
LTBI treatment post-screening. We defined migrants as 
any foreign-born individual.
We included publications reporting primary data on 
LTBI treatment uptake and adherence in migrant 
populations treated in the receiving country. Uptake 
was defined as a migrant initiating treatment after a 
positive test result. Adherence was defined as a migrant 
completing the course of required treatment after testing 
positive. There were no geographical or language 
restrictions regarding the publications included, and we 
included both adult and paediatric populations. We 
excluded case reports and case series because of the small 
number of individuals that these study types include. 
We also excluded publications with no primary data 
or discernible study design (eg, comments, editorials, 
letters, and reviews). We excluded studies with no clearly 
identifiable migrant population, or in which the definition 
of a migrant conflicted with our own (eg, defining 
migrant status on the basis of ancestry or ethnicity). 
We searched for publications from Jan 1, 2000, to 
April 21, 2020, excluding those that reported data from 
before 2000, or that had data after 2000 that could not be 
disaggregated. We chose 2000 as cutoff to better represent 
the rapidly evolving field in LTBI treatment in the past 
two decades, including contemporary treatments and 
global initiatives.
We searched the databases MEDLINE, Embase, and 
Global Health from Jan 1, 2000, to April 21, 2020, using a 
Boolean search strategy with keywords and relevant 
medical subheadings (MeSH) pertaining to three main 
themes: migrants, initiation and completion, and LTBI. 
Search terms were identified by consulting existing 
literature and experts in these areas. The search strategy 
and search terms are available in the appendix (pp 2–4) 
We explored the grey literature by hand-searching 
conference proceedings and the websites of relevant 
non-governmental and other organisations (eg, WHO). 
We identified additional publications through hand 
searching the bibliographies of publications included in 
the analysis. We compiled a list of experts in LTBI and 
emailed them formally requesting grey literature and 
publications that they were familiar with or programmatic 
data they were at liberty to divulge.
Two reviewers duplicated the title and abstract 
screening and full-text screening (KR, JL), which was 
done using the web-based application Rayyan.24 The 
reasons for excluding studies during full-text screening 
are shown in figure 1. Data were extracted by 
two reviewers (KR and JL). Where there were dis-
crepancies in screening decision, or the extracted data 
between the primary reviewers, a third reviewer (LBN or 
SH) mediated screening decisions and ensured the 
accuracy of extracted data.
This research was done in line with the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA),25 and registered with PROSPERO 
(CRD42019140338).
Data analysis
We used a piloted extraction form, which was developed 
among the research team, to retrieve data relating to 
treatment initiation and completion, alongside summary 
data on the study such as the design, dates, and 
location. We extracted summaries of analysis relating to 
positive and negative factors associated with the recorded 
initiation and completion of treatment within each 
See Online for appendix
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publication. Where data were available, we categorised 
each study according to: the WHO region where it took 
place; the decade the data were related to (2000–09 or 
2010–20); the type of migrants being studied (refugee, 
asylum seeker, undocumented, foreign-born); the 
treatment regimens used (6 months isoniazid, 9 months 
isoniazid, 6–9 months isoniazid, 3 months isoniazid plus 
rifampicin, 4 months rifampicin, mixed [including 
rifampicin and isoniazid regimens], and uncertain 
treatment regimen); treatment setting (a single site for 
screening and treatment, a single site for treatment only, 
multiple sites for screening and treatment, and multiple 
sites for treatment only; appendix pp 5–6).
We did all analysis in Stata/SE 16 using the metapreg 
command to calculate pooled proportions, as well as 
univariable and multi variable meta-regressions. Freeman-
Tukey double arcsine transformation was used, and 
95% CIs were calculated using Clopper-Pearson exact CIs 
in all instances.26,27 Heterogeneity between studies 
was estimated using the I² statistic; because of the 
heterogeneity of the included studies, all analyses used 
inverse-variance weighted random-effects models using 
the DerSimonian-Laird method.
We did a meta-analysis to calculate pooled estimates for 
three primary outcomes: the proportion of migrants 
positive for LTBI who initiated treatment, the proportion 
of migrants who, having initiated LTBI treatment, had 
completed it, and the overall proportion of migrants 
positive for LTBI who both successfully initiated and 
completed treatment. We also did a random-effects meta-
regression to analyse the influence of the variables 
indicated a priori and categorised during the extraction 
process on the three key outcomes. These variables were 
analysed using univariable meta-regression and those 
resulting in a p value of less than 0∙25 when testing 
heterogeneity between subgroups (appendix p 7) were 
included in a multivariable model that controlled for all 
other co-variates (table).
Narrative synthesis of positive and negative factors 
associated with LTBI treatment initiation and completion 
was done by extracting and reporting on factors found 
to significantly influence LTBI treatment initiation and 
completion within the included publications’ analyses.
Quality assessment was done for each included article 
using established appraisal tools (appendix pp 8–9). Cross-
sectional studies were assessed using the Joanna Briggs 
Institute checklist for prevalence studies.28 Cohort studies29 
and randomised controlled trials30 were assessed using 
their respective critical appraisal skills programme 
checklists. Using these tools, articles were given a quality 
score (appendix 5–6). For case-series and cohort studies, 
scores were calculated as a total out of the maximum 
number of applicable questions (pp 8–9). Quality scores 
are reported but studies were not excluded on the basis of 
quality to increase transparency and ensure that all 
available evidence in this field was reported. Critical 
appraisal was done in duplicate (KR and SEH).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Database and grey literature searches yielded 2199 pub-
lications, of which the full texts of 150 publications were 
screened and 39 were included in the review and meta-
analysis; (figure 1; appendix 5–6). The 39 included 
publications contained data on 31 598 migrants positive 
for LTBI. Studies were done in 13 countries, across three 
WHO regions (European region, region of the Americas, 
and Western Pacific region): Australia (n=4 studies),31–34 
Canada (n=3),35–37 Germany (n=1),38 Israel (n=1),39 
Japan (n=1),40 the Netherlands (n=2),41,42 Norway (n=2),43,44 
South Korea (n=1),45 Spain (n=3),46–48 Sweden (n=1),49 
Switzerland (n=1),50 UK (n=4),51–54 and USA (n=15).55–69
In total, 25 studies with outcome data on 8764 migrants 
were used to calculate the proportion of individuals 
initiating treatment.33–39,41–43,48,50–56,58–60,65,66,68,69 The pooled 
estimate for the true proportion of LTBI treatment 
initiation in migrants positive for LTBI across the 
included studies was calculated as 69% (95% CI 
51–84; 4409 of 8764, I²=99∙62% (95% CI 99∙58–99∙66; 
figure 2A). In univariable meta-regression, only the 
150 full-text articles assessed for eligibility
111 full-text articles excluded 
 36 could not disaggregate migrant outcomes 
 15 no migrant population 
 15 no data on uptake or adherence
 14 could not disaggregate data by date 
 14 data before 2000 
 6 not primary data 
 5 duplicate data or full publication available 
 4 could not disaggregate outcome measures
 2 not related to latent tuberculosis infection
39 articles included in qualitative synthesis meta-analysis
 25 articles had treatment initiation after positive test    
 35 articles had treatment completion after initiation
 35 articles had treatment completion after a positive test
2140 articles screened
1990 articles excluded
59 duplicate articles removed
2189 articles identified from database search 10 articles identified through other sources
Figure 1: PRISMA flow diagram of the article screening process
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decade in which individuals enrolled was found to have 
a significant effect. Specifically, studies that reported data 
in the 2010s showed higher proportions of treatment 
initiation (85% [95% CI 68–94]; p<0∙0001) than studies 
from the 2000s (43% [95% CI 19–71]; table; figure 3A).
Demographic and patient factors associated with non-
initiation of treatment reported in the studies were being 
of sub-Saharan African origin55 and being a refugee from 
sub-Saharan Africa, northern Africa, or the Middle East.69 
Factors positively associated with treatment initiation 
included having an African birthplace,60 close contact 
with a person with infectious tuberculosis,60 and non-
employment as a reason for LTBI testing.60 One study 
reported significantly higher treatment initiation in 
refugees than in other foreign-born groups and the 
native-born population.65 Reported clinical and systems-
related factors included testing with Quantiferon Test in 
refugees, which led to significantly higher proportion 
of individuals initiating treatment than when using 
Mantoux tuberculin skin testing.69 However, other 
studies found that non-initiation was associated with 
treatment not being offered59 and that recommendation 
to treat varied by primary care clinic.52
35 studies with outcome data on 25 629 migrants (of 
whom 15 516 completed treatment) were used to 
calculate the proportion of individuals completing 
treatment subsequent to initiation.32–42,44,45,47–51,53–69 The 
pooled estimate for the true proportion of LTBI treatment 
completion among migrants initiating treatment 
was 74% (95% CI 66–81; 15 516 of 25 629; I²=99∙19% 
[95% CI 99∙09–99∙28]; figure 2B). In univariable meta-
regression WHO region, the time period the data were 
related to, and the treatment regimen used were all 
significantly associated with treatment completion. In 
the multivariable model, migrants were more likely to 
complete treatment in the 2010s (88% [95% CI 81–92]; 
p<0∙0001) than in the 2000s (57% [95% CI 46–67]; ref). 
Migrants treated in the WHO European region were 
significantly more likely to complete treatment 
(87% [95% CI 78–92]; p<0∙0001) than migrants in the 
region of the Americas (66% [95% CI 55–75]; ref) or the 
Western Pacific region (75% [95% CI 55–88]; p=0∙82). 
Analysing by treatment regimen, migrants treated with 
4 months of rifampicin were significantly more likely to 
complete treatment (89% [95% CI 67–97]; p=0∙020) than 
migrants prescribed 9 months of isoniazid (ref); no 
other treatment regimen showed significant differences 
(table; figure 3B).
Demographic and patient-related factors associated 
with non-completion include unemployment,47 education 
level,47 and lack of family support.47 Demographic and 
patient-related factors associated with treatment 
completion included African or Asian birthplace 
(compared with a birthplace in the USA, Canada, 
western Europe, or Japan),60 being a refugee from 
South Asia,69 foreign-birth,44,64 having resided in the host 
country for less than 5 years,63 refugee status65 as well as 
migration from Europe or Asia.57 Two studies found no 
association between any demographic factors and 
treatment completion in either direction.66,67 Clinical and 
system-related factors associated with non-completion 
included side-effects,32,39,66 being prescribed a 3-month 
isoniazid plus rifampicin regimen compared with 
6 months of isoniazid,47 receiving 4 months of rifampicin 
compared with 9 months of isoniazid,63 6 months of 
Point estimate p value Raw coefficient (95% CI) 
change in outcome 
compared with the 
reference group
Treatment initiation among migrants positive for LTBI (univariable analysis only)
Time period
2000s 85% (ref) (ref)
2010s 43% <0∙0001 2∙10 (0∙51 to 3∙61)
Treatment completion among migrants that initiate treatment
WHO region
Region of the Americas 66% (ref) (ref)
European region 87% <0∙0001 0∙93 (0∙33 to 1∙54)
Western Pacific region 75% 0∙82 0∙09 (–0∙71 to 0∙89)
Time period
2000s 57% (ref) (ref)
2010s 88% <0∙0001 1∙45 (0∙82 to 2∙10)
Treatment regimen
9 months isoniazid 57% (ref) (ref)
6 months isoniazid 91% 0∙12 1∙17 (–0∙31 to 2∙65)
6–9 months isoniazid 71% 0∙21 0∙09 (–0∙75 to 0∙93)
3 months isoniazid plus 
rifampicin
86% 0∙48 –0∙37 (–1∙39 to 0∙66)
4 months rifampicin 89% 0∙020 1∙37 (0∙24 to 2∙50)
Mixed, including rifampicin 
and isoniazid
75% 0∙59 0∙21 (–0∙55 to 0∙96)
Unclear 56% 0∙22 –0∙65 (–1∙68 to 0∙39)
Treatment completion in migrants positive for LTBI
WHO region
Region of the Americas 44% (ref) (ref)
European region 70% 0∙020 1∙01 (0∙19 to 1∙83)
Western Pacific region 27% 0∙14 –0∙89 (–2∙07 to 0∙29)
Time period
2000s 26% (ref) (ref)
2010s 66% <0∙0001 1∙49 (0∙56 to 2∙42)
Treatment regimen
9 months isoniazid 37% (ref) (ref)
6 months isoniazid 42% 0∙74 0∙35 (–1∙76 to 2∙47)
6–9 months isoniazid 50% 0∙20 –1∙00 (–2∙51 to 0∙51)
3 months isoniazid plus 
rifampicin
74% 0∙42 –0∙55 (–1∙91 to 0∙81)
4 months rifampicin 70% 0∙96 0∙05 (–1∙76 to 1∙86)
Mixed, including rifampicin 
and isoniazid
50% 0∙58 –0∙35 (–1∙57 to 0∙87)
Unclear 38% 0∙070 –1∙01 (–2∙11 to 0∙09)
Results of statistical analysis of LTBI treatment initiation and completion outcomes in migrants. LBTI=latent tuberculosis 
infection.
Table: Meta-regression incorporating factors in which univariable analysis p value <0∙25
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isoniazid versus 9 months of isoniazid,49 receiving LTBI 
treatment in combination with immunosuppressive 
treatment,49 receiving treatment more recently (after 
2013),49 daily and weekly directly observed therapy versus 
self-administered care,44 and rifampicin versus isoniazid 
treatment.69
25 studies containing outcome data on 6652 migrants 
(of whom 3289 had initiated and completed treat-
ment) were used to calculate the overall proportion 
of migrants positive for LTBI who completed 
treatment.31,33–39,41,42,46,48,50,51,53–56,58–60,65,66,68,69 The pooled estimate 
for the true proportion of migrants completing treatment 
after screening positive for LTBI was 52% 
(95% CI 40–64; 3289 of 6652; I²=98∙90% [95% CI 
98∙73–99∙06]; figure 2C). In univariable meta-
regression, WHO region and time period of treatment 
receipt were significantly associated with treatment 
completion. In the multivariable model, migrants 
were more likely to complete treatment in the 2010s 
(66% [95% CI 52–77]; p<0∙0001) than migrants in the 
2000s (26% [95% CI 12–44]; ref). Migrants treated in the 
WHO European region were also significantly more 
likely to complete treatment (70% [95% CI 55–82]; 
p=0∙020) than migrants in the region of the Americas 
(44% [95% CI 31–58]; ref) and the Western Pacific region 
(27% [95% CI 11–53]; p=0∙14). In our analysis, no other 
factors were found to be significantly associated with 
completion (table; figure 3C).
Discussion
This systematic review and meta-analysis com pre-
hensively reports on pathway results for LTBI treatment 
outcomes for migrants. We identified evidence from 
13 mostly high-income, low-incidence tuberculosis 
countries and regional variation in treatment outcomes 
in migrants and approaches taken for treatment. Our 
analysis of 31 598 migrants positive for LTBI within the 
39 included studies showed that overall, between 
2000 and 2020 in studies reporting on the full initiation 
and treatment pathway, only 52% of migrants who tested 
positive for LTBI both initiated and completed treatment. 
We found that 69% of migrants with a positive LTBI test 
initiated treatment, and 74% of those who initiated 
treatment completed it. Overall, these data suggest that 
there is drop-out along the treatment pathway. These 
studies highlighted complex barriers and facilitators 
related to patient demographics and health systems and 
clinical decision making that affected outcomes. 
Improvements in the LTBI care cascade are needed, 
particularly with respect to the initiation of treatment of 
individuals who test positive. Our analysis suggests that 
the current approach requires renewed emphasis and 
strengthening, despite substantial improvements in 
outcomes in the past decade.
A previous review of LTBI initiation and completion 
found that treatment initiation rates in migrants ranged 
between 23% and 97%, and completion rates between 7% 
Figure 2: Meta-analysis forest plots estimating migrant LTBI patient treatment initiation and completion
Forest plots showing the proportion of migrants positive for LTBI who initiated treatment (A), the proportion of migrants who, having initiated LTBI treatment, had completed it (B), and the 
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Figure 3: Subgroup forest 
plots of individual variable 
estimates (time, WHO 
region, migrant type, site, 
and treatment regimen) for 
migrant LTBI patient 
treatment initiation and 
completion
Forest plots showing the 
proportion of migrants 
positive for LTBI who initiated 
treatment (A), the proportion 
of migrants who, having 
initiated LTBI treatment, had 
completed it (B), and the 
proportion of migrants 
positive for LTBI who 
successfully initiated and 
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and 86%.70 A further systematic review and meta-
analysis showed treatment initiation of 54∙6% and 
completion of 14∙3% in migrants.21 Our study builds on 
these estimates by calculating a pooled rate of initiation 
and completion specifically for migrant populations. 
Our estimation that approximately 74% of migrants who 
initiated LTBI treatment completed it in the period 
under study is markedly higher and more optimistic 
than the 14∙3% posited by previous research.21 However, 
our data on the entire pathway, from a migrant testing 
positive through to subsequent initiation and then 
completion of treatment, showed that our calculated 
rate of 52% is comparable to other studies, which 
suggests drop-out along the entire treatment trajectory.
Important sociodemographic and cultural factors might 
influence the decision of migrant patients to initiate and 
complete treatment. Stigma and misconceptions about 
the cause of tuberculosis can effect outcomes, and LTBI 
diagnosis can be misinterpreted as a tuberculosis diag-
nosis, with fears of stigma and social impact reflecting 
those of active tuberculosis.71 Clinicians also report 
difficulties in effectively communicating about LTBI with 
migrant patients and communities.23 Clinical practice and 
guidance are also important in supporting migrants to 
initiate treatment whereby differing clinical practices 
might result in non-initiation because of factors beyond 
the patients’ control.52,59,69 Deviation from national 
guidelines in health care has been evidenced in other 
research—eg, clinicians thinking that particular migrants 
are not eligible for preventive treatment, discrepancies 
around age thresholds for treatment, and other exclusion 
criteria.23,72 ECDC guidelines call for migrants who arrived 
within the past 5 years from high-tuberculosis-incidence 
countries to be screened for LTBI using a tuberculin skin 
test or an interferon-γ release assay and for these 
individuals to be linked to care and treatment.73 Toolkits 
supporting best practice for such guidelines exist, and 
could be further adapted to support treatment.74
More research is needed to assess facilitators to 
improve outcomes for LTBI in migrants. Crucially this 
research must better delineate what it is about being a 
migrant, or their experiences, that affects outcomes, 
which could be achieved through increased involvement 
of migrant communities across the entire research 
process, from inception to dissemination.
We found conflicting evidence as to whether foreign-
born status acts as a barrier or facilitator of treatment 
initiation and completion in the included studies. Studies 
using a binary foreign-born status appear to be most 
ambiguous, with some stating a positive association,44,64 
and some a negative association.40,61 Studies with greater 
granularity (eg, regional or country-specific analyses) 
produce a more nuanced picture, with divergent risk 
profiles for initiation and completion between migrant 
groups. These findings suggests that factors such as an 
individual’s country of origin, years of residency, and 
legal status provide important context beyond the scope 
of foreign-born status alone. Future research taking 
account of these factors could identify groups requiring 
greater treatment support. The composition of migrant 
groups might help to explain the disparate initiation and 
completion estimates in WHO regions, which have 
different migration flows.75 Interaction between factors 
associated with a migrants’ origin (cultural practices, 
medical beliefs) and the environment into which they 
migrate (access to care, availability of tailored services, 
resultant socioeconomic status), if disentangled, could 
also explain the differing levels of treatment initiation 
and completion seen between WHO regions.
Greater granularity in data could also contribute 
positively toward understanding the cost-effectiveness of 
LTBI screening and treatment, which continues to be a 
key question. Previous research indicates that the 
effectiveness and cost-effectiveness of LTBI screening 
and treatment is limited by factors such as the large pool 
of migrants with LTBI, diagnostics, and an insufficiently 
robust care cascade.76 Such programmes are therefore 
likely to be most effective when targeted, with success 
and evidence of cost-effectiveness being shown when 
focusing on migrant children, as an example.76,77
 Shorter treatment regimens were often associated 
with better outcomes in the analyses of included studies 
and might reduce drop-out. Evidence shows that shorter 
regimens might be as efficacious as longer treatment 
regimens, and are associated with greater compliance 
and less discontinuation because of hepatotoxicity and 
other side-effects.15 Shorter regimens are now also more 
widely recommended.15,19 A trial of tuberculosis patients 
with HIV infections showed that 1 month of daily 
rifapentine plus isoniazid treatment was non-inferior to 
9 months of isoniazid alone, and resulted in significantly 
more patients completing treatment.78 If similar ultra-
short course regimens can be prescribed, and other 
barriers overcome, treatment completion might increase. 
Although our analyses found little evidence of a 
significant association between treatment regimen and 
outcome, the type of regimen appeared to be associated 
with the time period under study with shorter and 
rifampicin-containing regimens seen in more recent 
studies. The influence of treatment regimen should not 
be discounted because of our analysis and an individual-
level patient data meta-analysis is probably better for 
analysing this association.
The work adheres to PRISMA standards and used a 
global multi-database search, with the input of expert 
groups, ensuring as much of the available literature as 
possible was captured. Furthermore, the meta-analysis 
provides a robust estimation of global LTBI treatment 
initiation and completion, and the factors driving these 
figures were explored through both meta-regression and 
narrative synthesis.
Our review is limited by the fact that potentially 
important factors outside of the immediate care setting 
are not effectively captured by studies in this field at 
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present, yet these factors are likely to influence both LTBI 
treatment initiation and completion. Furthermore, the 
binary definition that anyone foreign-born is a migrant can 
mask important differences resulting from differing legal 
status, and further excludes first-generation migrants (and 
beyond) who might have similar barriers. The use of meta-
regression is also not without limitations, often being 
underpowered to detect anything but large associations 
and any interpretation of the results are susceptible to 
ecological fallacy. As such, we would consider our analyses 
relating to meta-regression to be exploratory, and indicative 
of factors that might warrant more robust investigation in 
the future. Nevertheless, this systematic review and meta-
analysis provides important insight into the treatment 
outcomes of migrants with LTBI.
Contributors
SH had the idea for the study and KR, LBN, and JL were responsible for 
the study inception and protocol design. Database searches and screening 
were done by KR, LBN, and JL. Data extraction and analysis were done by 
KR, LBN, SH, JL, and SEH. KR, LBN, and SH have verified the data. 
Interpretation of the results and drafting of the manuscript was done by 
KR and SH, with input from all the authors. All authors commented on 
and approved the final manuscript. All authors had full access to all the 
data in the study, and the corresponding author had final responsibility 
for the decision to submit for publication.
Declaration of interests
SH is a freelance Senior Editor for The Lancet Infectious Diseases and other 
Lancet journals. All other authors declare no competing interests.
Data sharing
Materials including detailed critical appraisal and characteristics of each 
study are available in the appendices. The extracted data used within our 
analysis is available from the St George’s University data repository at 
https://doi.org/10.24376/rd.sgul.13521764.v1.
Acknowledgments
This study was funded by the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) through a joint ESCMID Study Group 
for Infections in Travellers and Migrants and ESCMID Study Group for 
Mycobacterial Infections Research grant. KR is funded by a Rosetrees 
Trust (PhD studentship grant M775). SH is funded by the National 
Institute for Health Research (NIHR; NIHR Advanced Fellowship 
NIHR300072) and the Academy of Medical Sciences (SBF005\1111). DG is 
a professor at Saint Camillus International University of Health and 
Medical Sciences in Rome. SEH is supported by a Medical Research 
Council PhD studentship (MR/N013638/1). DG reports support from the 
Italian Ministry of Health, Ricerca Corrente Linea 4. We would like to 
acknowledge the experts in the field who we contacted for grey literature 
and who contributed to the identification and screening of articles and 
data: Justin Denholm, Stephen Graham, Tanya Melillo, Pernille Ravn, 
and Gerard de Vries.
References
1 Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of 
latent tuberculosis: a systematic review and meta-analysis. 
Eur Respir J 2019; 54: 1900655.
2 Houben RMG, Dodd PJ. The global burden of latent tuberculosis 
infection: a re-estimation using mathematical modelling. PLoS Med 
2016; 13: e1002152.
3 Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive 
tuberculin reaction in childhood and adolescence. Am J Epidemiol 
1974; 99: 131–38.
4 Vynnycky E, Fine PE. The natural history of tuberculosis: 
the implications of age-dependent risks of disease and the role of 
reinfection. Epidemiol Infect 1997; 119: 183–201.
5 Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Risk of 
tuberculosis after recent exposure. A 10-year follow-up study of 
contacts in Amsterdam. Am J Respir Crit Care Med 2014; 
190: 1044–52.
6 WHO. The End TB Strategy. Geneva: World Health Organization, 
2015.
7 UN. Political declaration of the UN general assembly high-level 
meeting on the fight against tuberculosis. 2018. https://www.who.
int/tb/unhlmonTBDeclaration.pdf (accessed June 22, 2021).
8 WHO. Towards tuberculosis elimination: an action framework for 
low-incidence countries. Geneva: World Health Organization, 2014.
9 Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact 
of migration on tuberculosis epidemiology and control in high-
income countries: a review. BMC Med 2016; 14: 48.
10 Langholz Kristensen K, Lillebaek T, Holm Petersen J, et al. 
Tuberculosis incidence among migrants according to migrant 
status: a cohort study, Denmark, 1993 to 2015. Euro Surveill 2019; 
24: 1900238.
11 Eurostat. Asylum statistics. 2020. https://ec.europa.eu/eurostat/
statistics-explained/index.php/Asylum_statistics#Age_and_gender_
of_first-time_applicants (accessed June 22, 2021).
12 Baauw A, Kist-van Holthe J, Slattery B, Heymans M, Chinapaw M, 
van Goudoever H. Health needs of refugee children identified on 
arrival in reception countries: a systematic review and 
meta-analysis. BMJ Paediatr Open 2019; 3: e000516.
13 Fok A, Numata Y, Schulzer M, FitzGerald MJ. Risk factors for 
clustering of tuberculosis cases: a systematic review of population-
based molecular epidemiology studies. Int J Tuberc Lung Dis 2008; 
12: 480–92.
14 Aldridge RW, Zenner D, White PJ, et al. Tuberculosis in migrants 
moving from high-incidence to low-incidence countries: 
a population-based cohort study of 519 955 migrants screened 
before entry to England, Wales, and Northern Ireland. Lancet 2016; 
388: 2510–18.
15 WHO. Latent tuberculosis infection: updated and consolidated 
guidelines for programmatic management. Geneva: World Health 
Organization, 2018.
16 European Centre for Disease Prevention and Control. 
Programmatic management of latent tuberculosis infection in the 
European Union. Stockholm: European Centre for Disease 
Prevention and Control, 2018.
17 Dobler CC, Fox GJ, Douglas P, et al. Screening for tuberculosis in 
migrants and visitors from high-incidence settings: present and 
future perspectives. Eur Respir J 2018; 52: 1800591.
18 Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors 
for latent tuberculosis reactivation and their managements. 
Emerg Microbes Infect 2016; 5: e10.
19 Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of 
latent tuberculosis infection: recommendations from the National 
Tuberculosis Controllers Association and CDC, 2020. 
MMWR Recomm Rep 2020; 69: 1–11.
20 Seedat F, Hargreaves S, Nellums LB, Ouyang J, Brown M, 
Friedland JS. How effective are approaches to migrant screening for 
infectious diseases in Europe? A systematic review. Lancet Infect Dis 
2018; 18: e259–71.
21 Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. 
The cascade of care in diagnosis and treatment of latent 
tuberculosis infection: a systematic review and meta-analysis. 
Lancet Infect Dis 2016; 16: 1269–78.
22 Berrocal-Almanza LC, Botticello J, Piotrowski H, et al. Engaging 
with civil society to improve access to LTBI screening for new 
migrants in England: a qualitative study. Int J Tuberc Lung Dis 2019; 
23: 563–70.
23 Dobler CC, Bosnic-Anticevich S, Armour CL. Physicians’ 
perspectives on communication and decision making in clinical 
encounters for treatment of latent tuberculosis infection. 
ERJ Open Res 2018; 4: 4.
24 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. 
Rayyan—a web and mobile app for systematic reviews. 
Syst Rev 2016; 5: 210.
25 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that 
evaluate health care interventions: explanation and elaboration. 
PLoS Med 2009; 6: e1000100.
26 Nyaga VN. METAPREG: stata module to compute fixed and random 




www.thelancet.com/infection   Published online August 4, 2021   https://doi.org/10.1016/S1473-3099(21)00052-9 11
27 StataCorp. Stata Statistical Software: Release 16. 2019. https://www.
stata.com/ (accessed July 27, 2021).
28 The Joanna Briggs Institute. The Joanna Briggs Institute critical 
appraisal tool for use in JBI systematic reviews–checklist for 
prevalence studies 2017. https://jbi.global/sites/default/files/2019-05/
JBI_Critical_Appraisal-Checklist_for_Prevalence_Studies2017_0.pdf 
(accessed June 22, 2021).
29 Critical Appraisal Skills Programme. CASP Cohort Study Checklist. 
2018. https://casp-uk.net/wp-content/uploads/2018/03/CASP-Cohort-
Study-Checklist-2018_fillable_form.pdf (accessed June 22, 2021).
30 Critical Appraisal Skills Programme. CASP Randomised Controlled 
Trial Checklist. 2018. https://casp-uk.net/wp-content/
uploads/2018/03/CASP-Randomised-Controlled-Trial-Checklist-2018_
fillable_form.pdf (accessed June 22, 2021).
31 Sawka A, Brigham M, Barry S, Stapledon R. Five-year impact of a 
targeted screening program for latent tuberculosis infection in a 
high-risk population. Respirology 2019; 24: 40.
32 Dobler CC, Marks GB. Completion of treatment for latent 
tuberculosis infection with monthly drug dispensation directly 
through the tuberculosis clinic. PLoS One 2012; 7: e48900.
33 Elliot C, Marais B, Williams P, et al. Tuberculin skin test versus 
interferon-gamma release assay in refugee children: a retrospective 
cohort study. J Paediatr Child Health 2018; 54: 834–39.
34 Trauer JM, Krause VL. Assessment and management of latent 
tuberculosis infection in a refugee population in the Northern 
Territory. Med J Aust 2011; 194: 579–82.
35 Benjumea-Bedoya D, Becker M, Haworth-Brockman M, et al. 
Integrated care for latent tuberculosis infection (LTBI) at a primary 
health care facility for refugees in Winnipeg, Canada: a mixed-
methods evaluation. Front Public Health 2019; 7: 57.
36 Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-
based tuberculosis-screening program and associate investigation 
targeting recently immigrated children in a low-burden country. 
Pediatrics 2006; 117: e148–56.
37 Lim R, Jarand J, Field SK, Fisher D. Is Universal screening necessary? 
incidence of tuberculosis among Tibetan refugees arriving in Calgary, 
Alberta. Can Respir J 2016; 2016: 8249843.
38 Thee S, Krüger R, von Bernuth H, et al. Screening and treatment for 
tuberculosis in a cohort of unaccompanied minor refugees in Berlin, 
Germany. PLoS One 2019; 14: e0216234.
39 Bishara H, Ore L, Vinitsky O, Bshara H, Armaly N, Weiler-Ravell D. 
Cost of nurse-managed latent tuberculous infection treatment among 
hard-to-reach immigrants in Israel. Int J Tuberc Lung Dis 2015; 
19: 799–804.
40 Kawatsu L, Uchimura K, Ohkado A. Trend and treatment status of 
latent tuberculosis infection patients in Japan - analysis of Japan TB 
surveillance data. PLoS One 2017; 12: e0186588.
41 Spruijt I, Erkens C, Suurmond J, et al. Implementation of latent 
tuberculosis infection screening and treatment among newly arriving 
immigrants in the Netherlands: a mixed methods pilot evaluation. 
PLoS One 2019; 14: e0219252.
42 Spruijt I, Tesfay Haile D, Suurmond J, et al. Latent tuberculosis 
screening and treatment among asylum seekers: a mixed-methods 
study. Eur Respir J 2019; 54: 1900861.
43 Harstad I, Heldal E, Steinshamn SL, Garåsen H, Winje BA, 
Jacobsen GW. Screening and treatment of latent tuberculosis in a 
cohort of asylum seekers in Norway. Scand J Public Health 2010; 
38: 275–82.
44 Schein YL, Madebo T, Andersen HE, et al. Treatment completion for 
latent tuberculosis infection in Norway: a prospective cohort study. 
BMC Infect Dis 2018; 18: 587.
45 Kim BK, Kim HJ, Kim HJ, et al. Experiences of latent tuberculosis 
infection treatment for the North Korean refugees. 
Tuberc Respir Dis (Seoul) 2019; 82: 306–10.
46 Essadek HO, Mendioroz J, Guiu IC, et al. Community strategies to 
tackle tuberculosis according to the WHO region of origin of 
immigrant communities. Public Health Action 2018; 8: 135–40.
47 Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, 
Solsona Peiró J, Altet-Gómez MN. Rifampicin plus isoniazid for the 
prevention of tuberculosis in an immigrant population. 
Int J Tuberc Lung Dis 2013; 17: 326–32.
48 Villa S, Codecasa LR, Faccini M, et al. Tuberculosis among asylum 
seekers in Milan, Italy: epidemiological analysis and evaluation of 
interventions. Eur Respir J 2019; 54: 1900896.
49 Olsson O, Winqvist N, Olsson M, Olsson P, Björkman P. High rate 
of latent tuberculosis treatment completion in immigrants seeking 
asylum in Sweden. Infect Dis (Lond) 2018; 50: 678–86.
50 Bodenmann P, Vaucher P, Wolff H, et al. Screening for latent 
tuberculosis infection among undocumented immigrants in Swiss 
healthcare centres; a descriptive exploratory study. BMC Infect Dis 
2009; 9: 34.
51 Hargreaves S, Seedat F, Car J, et al. Screening for latent TB, HIV, 
and hepatitis B/C in new migrants in a high prevalence area of 
London, UK: a cross-sectional study. BMC Infect Dis 2014; 14: 657.
52 Loutet MG, Burman M, Jayasekera N, et al. National roll-out of 
latent tuberculosis testing and treatment for new migrants 
in England: a retrospective evaluation in a high-incidence area. 
Eur Respir J 2018; 51: 1701226.
53 O’Shea MK, Fletcher TE, Beeching NJ, et al. Tuberculin skin 
testing and treatment modulates interferon-gamma release assay 
results for latent tuberculosis in migrants. PLoS One 2014; 
9: e97366.
54 Usdin M, Dedicoat M, Gajraj R, et al. Latent tuberculous screening 
of recent migrants attending language classes: a cohort study and 
cost analysis. Int J Tuberc Lung Dis 2017; 21: 175–80.
55 Bennett RJ, Brodine S, Waalen J, Moser K, Rodwell TC. Prevalence 
and treatment of latent tuberculosis infection among newly arrived 
refugees in San Diego County, January 2010–October 2012. 
Am J Public Health 2014; 104: e95–102.
56 Carter KL, Gabrellas AD, Shah S, Garland JM. Improved latent 
tuberculosis therapy completion rates in refugee patients 
through use of a clinical pharmacist. Int J Tuberc Lung Dis 2017; 
21: 432–37.
57 Chang AH, Polesky A, Bhatia G. House calls by community health 
workers and public health nurses to improve adherence to isoniazid 
monotherapy for latent tuberculosis infection: a retrospective study. 
BMC Public Health 2013; 13: 894.
58 Duchen D, Boyd AT, Annamalai A. Screening and treatment rates 
for latent tuberculosis among newly-arrived refugees in an urban 
facility in Connecticut. Conn Med 2017; 81: 291–98.
59 Gacek P, Sosa L, Lobato MN. Assessment of postarrival tuberculosis 
examinations among immigrants and refugees screened overseas. 
Conn Med 2013; 77: 325–30.
60 Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of 
latent tuberculosis treatment initiation and completion at a U.S. 
public health clinic: a prospective cohort study. BMC Public Health 
2012; 12: 468.
61 Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, 
Kainer MA. Successful use of rifampicin for Hispanic foreign-born 
patients with latent tuberculosis infection. Int J Tuberc Lung Dis 
2008; 12: 160–67.
62 Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. 
Predictors of latent tuberculosis infection treatment completion in 
the United States: an inner city experience. Int J Tuberc Lung Dis 
2010; 14: 1104–11.
63 Lardizabal A, Passannante M, Kojakali F, Hayden C, 
Reichman LB. Enhancement of treatment completion for latent 
tuberculosis infection with 4 months of rifampin. Chest 2006; 
130: 1712–17.
64 Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to 
treatment of latent tuberculosis infection in a clinical population in 
New York City. Int J Infect Dis 2010; 14: e292–97.
65 Nuzzo JB, Golub JE, Chaulk P, Shah M. Analysis of latent 
tuberculosis infection treatment adherence among refugees and 
other patient groups referred to the Baltimore City Health 
Department TB clinic, February 2009–March 2011. 
J Immigr Minor Health 2015; 17: 56–65.
66 Ailinger RL, Black P, Nguyen N, Lasus H. Predictors of adherence 
to latent tuberculosis infection therapy in Latino immigrants. 
J Community Health Nurs 2007; 24: 191–98.
67 Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, 
Saukkonen JJ. Predicting non-completion of treatment for latent 
tuberculous infection: a prospective survey. Am J Respir Crit Care Med 
2006; 174: 717–21.
68 Subedi P, Drezner KA, Dogbey MC, et al. Evaluation of latent 
tuberculous infection and treatment completion for refugees 
in Philadelphia, PA, 2010-2012. Int J Tuberc Lung Dis 2015; 
19: 565–69.
Articles
12 www.thelancet.com/infection   Published online August 4, 2021   https://doi.org/10.1016/S1473-3099(21)00052-9
69 Walters JK, Sullivan AD. Impact of Routine quantiferon testing on 
latent tuberculosis diagnosis and treatment in refugees in 
Multnomah County, Oregon, November 2009-October 2012. 
J Immigr Minor Health 2016; 18: 292–300.
70 Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, 
Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and 
completion rates for latent tuberculosis infection treatment: 
a systematic review. BMC Infect Dis 2016; 16: 204.
71 Gao J, Berry NS, Taylor D, Venners SA, Cook VJ, Mayhew M. 
Knowledge and perceptions of latent tuberculosis infection among 
Chinese immigrants in a Canadian Urban Centre. Int J Family Med 
2015; 2015: 546042.
72 White HA, Miller RF, Pozniak AL, et al. Latent tuberculosis 
infection screening and treatment in HIV: insights from evaluation 
of UK practice. Thorax 2017; 72: 180–82.
73 European Centre for Disease Prevention and Control. Public health 
guidance on screening and vaccination for infectious diseases in 
newly arrived migrants within the EU/EEA. Stockholm: European 
Centre for Disease Prevention and Control, 2018.
74 TB Alert, NHS England, Public Health England. Access, testing and 




75 Abel GJ, Sander N. Quantifying global international migration 
flows. Science 2014; 343: 1520–22.
76 Greenaway C, Pareek M, Abou Chakra CN, et al. The effectiveness 
and cost-effectiveness of screening for latent tuberculosis among 
migrants in the EU/EEA: a systematic review. Euro Surveill 2018; 
23: 17-0054.
77 Usemann J, Ledergerber M, Fink G, Ritz N. Cost-effectiveness of 
tuberculosis screening for migrant children in low-incidence 
countries. Eur Respir J 2018; 23: 579–86.
78 Swindells S, Ramchandani R, Gupta A, et al. One month of 
rifapentine plus isoniazid to prevent HIV-related tuberculosis. 
N Engl J Med 2019; 380: 1001–11.
